Envista (NVST)
(Delayed Data from NYSE)
$19.06 USD
+0.06 (0.32%)
Updated May 6, 2024 04:00 PM ET
After-Market: $19.05 -0.01 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.06 USD
+0.06 (0.32%)
Updated May 6, 2024 04:00 PM ET
After-Market: $19.05 -0.01 (-0.05%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum C VGM
Zacks News
SmileDirectClub (SDC) to Boost Europe Presence, Enter France
by Zacks Equity Research
SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment
by Zacks Equity Research
Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
NextGen's (NXGN) New Partnership to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
Abbott's (ABT) Portico With FlexNav System Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
Here's Why You Should Retain Walgreens (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes
by Zacks Equity Research
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan
by Zacks Equity Research
Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.
Henry Schein (HSIC) Betters Strategic View With Restructure Plan
by Zacks Equity Research
Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
by Zacks Equity Research
The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio
by Zacks Equity Research
NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.
Align Technology (ALGN) Launches Professional Whitening System
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities
by Zacks Equity Research
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.